OCUGEN, INC. Payments of Financing Costs
OCUGEN, INC. (OCGN) reported Payments of Financing Costs of $0 for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-07.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfFinancingCosts · last filed 2021-05-07
- OCUGEN, INC. payments of financing costs for the quarter ending 2021-03-31 was $0.00, a 100.00% decline year-over-year.
- OCUGEN, INC. payments of financing costs for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- OCUGEN, INC. payments of financing costs for the quarter ending 2020-06-30 was -$260.00.
- OCUGEN, INC. payments of financing costs for the quarter ending 2020-03-31 was $6.00K, a 92.96% decline year-over-year.
| Period end | Payments of Financing Costs 3 month | Payments of Financing Costs 3 month as first filed | Payments of Financing Costs 6 month | Payments of Financing Costs 9 month |
|---|---|---|---|---|
| 2021-03-31 | $0.00 10-Q · filed 2021-05-07 | |||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | -$260.00 derived: sum of 2 quarters · filed 2020-11-06 | $5.74K 10-Q · filed 2020-11-06 | |
| 2020-06-30 | -$260.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $5.74K 10-Q · filed 2020-08-14 | ||
| 2020-03-31 | $6.00K 10-Q · filed 2021-05-07 | $5.74K 10-Q · filed 2020-05-08 | ||
| 2019-09-30 | $37.03K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $37.03K derived: sum of 2 quarters · filed 2020-11-06 | $122.26K 10-Q · filed 2020-11-06 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $85.23K 10-Q · filed 2020-08-14 | ||
| 2019-03-31 | $85.23K 10-Q · filed 2020-05-08 | |||
| 2018-06-30 | $38.97K 8-K/A · filed 2019-10-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |